Adenocarcinoma as an Independent Risk Factor for Disease Recurrence in Patients with Stage IB Cervical Carcinoma

Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (...

Full description

Saved in:
Bibliographic Details
Published inGynecologic oncology Vol. 59; no. 1; pp. 38 - 44
Main Authors Eifel, P.J., Burke, T.W., Morris, M., Smith, T.L.
Format Journal Article Conference Proceeding
LanguageEnglish
Published San Diego, CA Elsevier Inc 01.10.1995
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively ( P < 0.01). Patients with AC more often had a maximum cervical diameter <4 cm than those with SCC (53% versus 47%). For 903 patients with tumors ⩾4 cm, 73% of those with SCC survived ⩾5 years compared with only 59% of those with AC ( P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors ⩾4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P < 0.01). For patients with tumors ⩾4 cm, prognosis was strongly correlated with tumor size ( P < 0.01) and lymphangiogram findings ( P < 0.01) but not with age ( P = 0.58) or tumor morphology (exophytic versus endocervical) ( P = 0.33); a trend toward better survival in 165 patients wire underwent adjuvant hysterectomy (78% versus 71%) was not significant ( P = 11.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors ⩾4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC ( P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC.
AbstractList Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (P < 0.01). Patients with AC more often had a maximum cervical diameter < 4 cm than those with SCC (53% versus 47%). For 903 patients with tumors > or = 4 cm, 73% of those with SCC survived > or = 5 years compared with only 59% of those with AC (P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors > or = 4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P < 0.01). For patients with tumors > or = 4 cm, prognosis was strongly correlated with tumor size (P < 0.01) and lymphangiogram findings (P < 0.01) but not with age (P = 0.58) or tumor morphology (exophytic versus endocervical) (P = 0.33); a trend toward better survival in 165 patients who underwent adjuvant hysterectomy (78% versus 71%) was not significant (P = 0.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors > or = 4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC (P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC.
Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (P &lt; 0.01). Patients with AC more often had a maximum cervical diameter &lt; 4 cm than those with SCC (53% versus 47%). For 903 patients with tumors &gt; or = 4 cm, 73% of those with SCC survived &gt; or = 5 years compared with only 59% of those with AC (P &lt; 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors &gt; or = 4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P &lt; 0.01). For patients with tumors &gt; or = 4 cm, prognosis was strongly correlated with tumor size (P &lt; 0.01) and lymphangiogram findings (P &lt; 0.01) but not with age (P = 0.58) or tumor morphology (exophytic versus endocervical) (P = 0.33); a trend toward better survival in 165 patients who underwent adjuvant hysterectomy (78% versus 71%) was not significant (P = 0.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors &gt; or = 4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC (P &lt; 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC.
Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively ( P < 0.01). Patients with AC more often had a maximum cervical diameter <4 cm than those with SCC (53% versus 47%). For 903 patients with tumors ⩾4 cm, 73% of those with SCC survived ⩾5 years compared with only 59% of those with AC ( P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors ⩾4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P < 0.01). For patients with tumors ⩾4 cm, prognosis was strongly correlated with tumor size ( P < 0.01) and lymphangiogram findings ( P < 0.01) but not with age ( P = 0.58) or tumor morphology (exophytic versus endocervical) ( P = 0.33); a trend toward better survival in 165 patients wire underwent adjuvant hysterectomy (78% versus 71%) was not significant ( P = 11.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors ⩾4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC ( P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC.
Author Eifel, P.J.
Morris, M.
Burke, T.W.
Smith, T.L.
Author_xml – sequence: 1
  givenname: P.J.
  surname: Eifel
  fullname: Eifel, P.J.
– sequence: 2
  givenname: T.W.
  surname: Burke
  fullname: Burke, T.W.
– sequence: 3
  givenname: M.
  surname: Morris
  fullname: Morris, M.
– sequence: 4
  givenname: T.L.
  surname: Smith
  fullname: Smith, T.L.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3697185$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/7557613$$D View this record in MEDLINE/PubMed
BookMark eNp1kEtPWzEQRi1EBYF2y66SF1V3N9hx_FrSlEckpFa0XVsTe0JNEzu1b0D8e3yVwI6F7cUcfzNzTshhygkJOeNszBlT5_fPKY-5tXLMJ0oekBFnVnbKSHtIRoxZ1pmJNMfkpNYHxphgfHJEjrSUWnExIpuLgCl7KD6mvAYKlUKi8xRwg-1KPb2L9R-9At_nQpftfI8VoSK9Q78tBZNHGhP9CX1sdKVPsf9Lf_Vwj3T-jc6wPEYPKzp77fCRfFjCquKn_XtK_lxd_p7ddLc_ruezi9vOC2X6bmomEIwJxkqjPTcKBC5QGAYcNUirlfIMFlwIzlEy681CBwhT7dtmjE_FKfm6y92U_H-LtXfrWD2uVpAwb6vTTUEzwBs43oG-5FoLLt2mxDWUZ8eZGxS7QbEbFLtBcfvweZ-8XawxvOF7p63-ZV-H2lZfFkg-1jdMKKu5GWLMDsNm4TFicdXHQWeIBX3vQo7vTfACdaqZKQ
CODEN GYNOA3
CitedBy_id crossref_primary_10_1046_j_1525_1438_2000_010004305_x
crossref_primary_10_1097_IGC_0000000000001009
crossref_primary_10_1016_j_gofs_2019_02_006
crossref_primary_10_1177_0300060518803041
crossref_primary_10_1007_s00066_012_0123_2
crossref_primary_10_1111_j_1525_1438_2005_00164_x
crossref_primary_10_1097_IGC_0000000000001088
crossref_primary_10_1016_S1297_9589_02_00318_1
crossref_primary_10_1111_jog_13282
crossref_primary_10_1111_j_1349_7006_2010_01812_x
crossref_primary_10_1016_j_radonc_2014_03_025
crossref_primary_10_17116_onkolog20176176_80
crossref_primary_10_1186_s12885_022_10277_0
crossref_primary_10_1007_s10147_008_0861_4
crossref_primary_10_1016_j_ygyno_2013_01_007
crossref_primary_10_1002_cncr_11679
crossref_primary_10_1016_j_jfma_2012_10_021
crossref_primary_10_1002_1097_0142_20011101_92_9_2471__AID_CNCR1597_3_0_CO_2_K
crossref_primary_10_1038_s41598_020_73523_0
crossref_primary_10_1016_j_ijrobp_2010_07_011
crossref_primary_10_1111_j_1525_1438_2008_01195_x
crossref_primary_10_1002_ijc_22678
crossref_primary_10_1016_j_ijrobp_2004_04_030
crossref_primary_10_1016_j_asjsur_2021_06_063
crossref_primary_10_1006_gyno_1998_5046
crossref_primary_10_1200_JCO_2017_77_3416
crossref_primary_10_1016_S0360_3016_98_00255_7
crossref_primary_10_1158_1078_0432_CCR_09_0560
crossref_primary_10_1016_j_ygyno_2013_04_470
crossref_primary_10_1002_14651858_CD006248_pub3
crossref_primary_10_1016_S0002_9378_98_70313_8
crossref_primary_10_1097_IGC_0000000000000263
crossref_primary_10_1038_sj_bjc_6605705
crossref_primary_10_1046_j_1525_1438_2002_01089_x
crossref_primary_10_1186_s12920_022_01376_9
crossref_primary_10_1007_s12253_015_9906_y
crossref_primary_10_1016_j_ygyno_2021_08_004
crossref_primary_10_1016_S0959_8049_02_00315_5
crossref_primary_10_1016_S0889_8545_02_00023_2
crossref_primary_10_1016_j_semradonc_2011_12_009
crossref_primary_10_1006_gyno_2000_5935
crossref_primary_10_1006_gyno_2001_6473
crossref_primary_10_1006_gyno_1998_5291
crossref_primary_10_1016_j_ejogrb_2006_10_021
crossref_primary_10_1016_j_ejso_2005_01_003
crossref_primary_10_1016_j_ijsu_2017_03_024
crossref_primary_10_1016_j_plefa_2008_10_003
crossref_primary_10_18632_aging_205397
crossref_primary_10_1016_j_omto_2020_09_001
crossref_primary_10_1002_cncr_11371
crossref_primary_10_1007_s11864_015_0386_9
crossref_primary_10_1159_000511564
crossref_primary_10_1006_gyno_1999_5434
crossref_primary_10_1093_jjco_hyz200
crossref_primary_10_1097_IGC_0000000000000650
crossref_primary_10_1002_ijc_30636
crossref_primary_10_1016_j_ygyno_2014_08_014
crossref_primary_10_1016_j_ygyno_2007_07_080
crossref_primary_10_3390_medicina56040152
crossref_primary_10_3802_jgo_2013_24_3_222
crossref_primary_10_1093_ajcp_aqx077
crossref_primary_10_5402_2012_817065
crossref_primary_10_1002_jso_21499
crossref_primary_10_1016_j_path_2010_12_006
crossref_primary_10_1007_s00261_016_0825_5
crossref_primary_10_1016_j_ygyno_2006_01_009
crossref_primary_10_1186_s12905_022_01971_z
crossref_primary_10_1038_sj_bjc_6605048
crossref_primary_10_1016_j_ejogrb_2011_12_029
crossref_primary_10_1586_eog_11_74
crossref_primary_10_3802_jgo_2017_28_e81
crossref_primary_10_1016_j_gyobfe_2003_10_028
crossref_primary_10_1016_j_ijsu_2017_05_074
crossref_primary_10_1097_IGC_0000000000000763
crossref_primary_10_1159_000369387
crossref_primary_10_1046_j_1525_1438_1999_09895_x
crossref_primary_10_1002_cam4_971
crossref_primary_10_2165_00024669_200302040_00004
crossref_primary_10_1007_s10147_017_1225_8
crossref_primary_10_1016_j_jfma_2022_10_012
crossref_primary_10_1016_j_vaccine_2011_09_115
crossref_primary_10_3802_jgo_2022_33_e82
crossref_primary_10_3892_mco_2013_112
crossref_primary_10_1016_j_ejogrb_2019_01_028
crossref_primary_10_1620_tjem_254_145
crossref_primary_10_1002_1097_0142_20011215_92_12_2999__AID_CNCR10145_3_0_CO_2_1
crossref_primary_10_16919_bozoktip_467455
crossref_primary_10_1016_j_ijrobp_2010_02_009
crossref_primary_10_1007_s11033_013_2969_5
crossref_primary_10_1158_1078_0432_CCR_07_4085
crossref_primary_10_1007_s00259_009_1336_1
crossref_primary_10_1002_ijc_21813
crossref_primary_10_1016_S0360_3016_02_04525_X
crossref_primary_10_1111_j_1048_891X_2004_014504_x
crossref_primary_10_1016_j_clon_2008_03_001
crossref_primary_10_1016_j_ygyno_2003_08_020
crossref_primary_10_1016_j_ygyno_2015_05_016
crossref_primary_10_1111_j_1525_1438_2006_00628_x
crossref_primary_10_1038_bjc_2013_716
crossref_primary_10_1016_j_brachy_2022_06_009
crossref_primary_10_1002_cncr_24822
crossref_primary_10_1097_IGC_0000000000000197
crossref_primary_10_1080_01443615_2016_1245279
crossref_primary_10_1016_j_ygyno_2015_06_035
crossref_primary_10_3802_jgo_2017_28_e34
crossref_primary_10_1111_j_1048_891X_2004_014211_x
crossref_primary_10_1016_j_ygyno_2014_01_048
crossref_primary_10_1016_j_ygyno_2011_06_024
crossref_primary_10_1093_jjco_hyq053
crossref_primary_10_1016_j_ijrobp_2011_12_013
crossref_primary_10_1016_j_ygyno_2012_06_024
crossref_primary_10_15406_jcpcr_2015_02_00058
crossref_primary_10_1007_s10147_016_1010_0
crossref_primary_10_1097_PGP_0000000000000612
crossref_primary_10_1002_cncr_28916
crossref_primary_10_1046_j_1525_1438_1998_09796_x
crossref_primary_10_1054_cuog_2000_0108
crossref_primary_10_1245_s10434_008_0185_7
crossref_primary_10_1186_s12885_018_5007_0
crossref_primary_10_7314_APJCP_2014_15_6_2815
crossref_primary_10_1007_s11912_015_0440_6
crossref_primary_10_3892_ol_2015_3105
crossref_primary_10_1016_j_ijgo_2011_06_011
crossref_primary_10_1046_j_1525_1438_1999_09873_x
crossref_primary_10_1016_j_ygyno_2014_10_004
crossref_primary_10_1097_MD_0000000000009323
crossref_primary_10_1016_j_ajog_2011_07_029
crossref_primary_10_1245_s10434_012_2768_6
crossref_primary_10_3802_jgo_2011_22_1_32
crossref_primary_10_1371_journal_pone_0122557
crossref_primary_10_1097_IGC_0000000000000063
crossref_primary_10_1186_s12893_023_02203_3
crossref_primary_10_1016_j_ejro_2022_100433
crossref_primary_10_1016_S0046_8177_98_90117_4
crossref_primary_10_1016_j_ygyno_2012_01_034
crossref_primary_10_1007_s00404_010_1511_4
crossref_primary_10_1007_s11912_014_0416_y
crossref_primary_10_1186_1471_2407_13_553
crossref_primary_10_1093_jrr_rrt086
crossref_primary_10_4236_ojog_2014_414128
crossref_primary_10_1155_2020_3981529
crossref_primary_10_1006_gyno_1998_5093
crossref_primary_10_1136_ijgc_2019_000647
crossref_primary_10_1590_1806_93042019000300009
crossref_primary_10_1016_j_ijgo_2010_08_016
crossref_primary_10_3892_mco_2014_295
crossref_primary_10_18632_oncotarget_17574
crossref_primary_10_1371_journal_pone_0139748
crossref_primary_10_1186_1471_2407_7_164
crossref_primary_10_1016_S0895_6111_97_00007_4
crossref_primary_10_1007_s00280_017_3402_x
crossref_primary_10_1016_j_critrevonc_2019_01_006
crossref_primary_10_5301_tj_5000697
crossref_primary_10_1002_cncr_24400
crossref_primary_10_3892_ol_2015_3015
crossref_primary_10_1016_j_ygyno_2007_02_019
crossref_primary_10_1016_j_ygyno_2009_09_040
crossref_primary_10_1006_gyno_1997_4886
crossref_primary_10_1111_IGC_0b013e3181a12ea6
crossref_primary_10_1016_j_neo_2018_08_010
crossref_primary_10_18632_oncotarget_12598
crossref_primary_10_1158_1055_9965_EPI_08_0965
crossref_primary_10_3390_ijms21114117
crossref_primary_10_1002_jcb_28007
crossref_primary_10_1016_j_ejogrb_2020_06_030
crossref_primary_10_1016_j_ygyno_2007_01_045
crossref_primary_10_5794_jjoms_59_617
crossref_primary_10_1006_gyno_1998_4971
crossref_primary_10_1016_j_ygyno_2012_03_008
crossref_primary_10_1016_j_jgyn_2012_07_003
crossref_primary_10_1016_j_ejso_2024_107977
crossref_primary_10_1016_j_ajog_2007_08_055
crossref_primary_10_1067_mob_2002_127906
crossref_primary_10_1006_gyno_1999_5364
crossref_primary_10_1016_j_ygyno_2010_11_022
crossref_primary_10_1002_cncr_28288
crossref_primary_10_1002_cncr_28722
crossref_primary_10_1002_ijc_34242
crossref_primary_10_1016_j_ajog_2005_06_029
crossref_primary_10_1016_j_ogc_2012_02_008
crossref_primary_10_1007_s00262_015_1678_4
crossref_primary_10_1007_s40944_022_00677_2
crossref_primary_10_1097_00006250_199902000_00012
crossref_primary_10_3390_cancers14163934
crossref_primary_10_1097_IGC_0b013e3182a3402f
ContentType Journal Article
Conference Proceeding
Copyright 1995 Academic Press
1995 INIST-CNRS
Copyright_xml – notice: 1995 Academic Press
– notice: 1995 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1006/gyno.1995.1265
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1095-6859
EndPage 44
ExternalDocumentID 10_1006_gyno_1995_1265
7557613
3697185
S0090825885712656
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29I
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AAXUO
ABBQC
ABFNM
ABFRF
ABJNI
ABLVK
ABMAC
ABMZM
ABXDB
ABYKQ
ACDAQ
ACGFO
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AEVXI
AFCTW
AFFNX
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AHPSJ
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJRQY
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DM4
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HED
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LCYCR
LG5
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OQ.
OZT
P-8
P-9
P2P
PC.
PH~
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSZ
T5K
UDS
UHS
UV1
WUQ
X7M
XPP
Z5R
ZGI
ZMT
ZU3
ZXP
~G-
08R
AAPBV
AAUGY
ABPIF
ABPTK
IQODW
AAXKI
AFJKZ
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c368t-482ad88d89587c186a3ebe380a1e7a59766c0ab13311e509c8b7dad47c5570143
IEDL.DBID AIKHN
ISSN 0090-8258
IngestDate Fri Oct 25 23:00:39 EDT 2024
Thu Sep 26 18:59:08 EDT 2024
Sat Sep 28 07:34:29 EDT 2024
Sun Oct 22 16:08:28 EDT 2023
Fri Feb 23 02:25:58 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Adenocarcinoma
Human
Relapse
Carcinoma
Prognosis
Early stage
Histology
Malignant tumor
Uterine cervix
Statistical study
Female genital diseases
Follow up study
Risk factor
Female
Uterine cervix diseases
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c368t-482ad88d89587c186a3ebe380a1e7a59766c0ab13311e509c8b7dad47c5570143
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 7557613
PQID 77556131
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_77556131
crossref_primary_10_1006_gyno_1995_1265
pubmed_primary_7557613
pascalfrancis_primary_3697185
elsevier_sciencedirect_doi_10_1006_gyno_1995_1265
PublicationCentury 1900
PublicationDate 1995-10-01
PublicationDateYYYYMMDD 1995-10-01
PublicationDate_xml – month: 10
  year: 1995
  text: 1995-10-01
  day: 01
PublicationDecade 1990
PublicationPlace San Diego, CA
PublicationPlace_xml – name: San Diego, CA
– name: United States
PublicationTitle Gynecologic oncology
PublicationTitleAlternate Gynecol Oncol
PublicationYear 1995
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
SSID ssj0003012
Score 1.9750477
Snippet Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients...
SourceID proquest
crossref
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 38
SubjectTerms Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - radiotherapy
Adult
Biological and medical sciences
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - radiotherapy
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - epidemiology
Neoplasm Staging
Risk Factors
Survival Rate
Treatment Outcome
Tumors
Uterine Cervical Neoplasms - mortality
Uterine Cervical Neoplasms - pathology
Uterine Cervical Neoplasms - radiotherapy
Title Adenocarcinoma as an Independent Risk Factor for Disease Recurrence in Patients with Stage IB Cervical Carcinoma
URI https://dx.doi.org/10.1006/gyno.1995.1265
https://www.ncbi.nlm.nih.gov/pubmed/7557613
https://search.proquest.com/docview/77556131
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFH6CIiGkCbENNDYKPkzaKTR2Ets5lkLVrgJN1RDcLNtxUYWWVqQ9cOFv33OcVOLQC6cosZw8vc957_OP9x7ATxnnTBTWRq6YmSiV6Swy8cxFzOWWJWlsc-2jkW_v-Og-_f2YPe7AoI2F8ccqG9sfbHptrZsnvUabveV87mN8fbnuTMpMUIa0ZBf20B0x2YG9_ngyutsYZBzDIWl4HTWdyTZ3Y8x7T6_lwgfsZZf-Fdt806elrlBjs1DqYjsXrX3S8AgOGzJJ-kHez7Djyi-wf9tsl3-FZR-tCjqrF7xd_NNEV0SXZLypfLsi03n1TIZ1zR2C9JVch_0aMvXL8HUgIJmX5E9IvloRv2pLkJ8-OTK-IoPazqAAg_YLx3A_vPk7GEVNiYXIJlyuEBymCykLmWdSWCq5ThDVRMaaOqFxssG5jbXBiSylDrmFlUYUukiF9am7kGudQKdclO4bEK4ZNQk1udEpcrTExNpSExcF00izGD2FX61y1TJk0lAhZzJXHgblYVAehlOgre7Vu7Gg0Mxv7dN9B9LmEwnP0f1i-0ULmsIfyO-K6NIt1pUSwlcITVC-k4Dlpis2CGz5_gFxfsBBHften_o7g87qZe26yF5W5hx2L9_oeTNG_XUyfZj8B9378GA
link.rule.ids 310,311,315,783,787,792,793,4509,23942,23943,24128,25152,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZ4SICEEE9RXvWAxBQa52E7IxSqFlqEEEhslu24qEKkVVMGFn47ZzspYujCmFhOTvdd7r7YvjuEznmYRSzXOjD5UAUJT4aBCocmiEymozgJdSZtNvLggXZfkrvX9HUJtetcGHussvL93qc7b13daVXabE1GI5vja9t1p5ynjERAS5bRamL5MRj15ffvOQ-wYF8y3OVMp7yu3BjS1ttXMbbpeumlfcCiyLQ5kSXoa-gbXSxmoi4idbbRVkUl8ZWXdgctmWIXrQ2qzfI9NLkCnwKhagqX4w-JZYllgXvzvrcz_DQq33HHddzBQF7xjd-twU92Ed6lAeJRgR996dUS2zVbDOz0zeDeNW47LwMCtOs37KOXzu1zuxtUDRYCHVM-A2gimXOe8yzlTBNOZQyYxjyUxDAJqqRUh1LBbywhBpiF5orlMk-YtoW7gGkdoJViXJhDhKmMiIqJypRMgKHFKpSaqDDPIwkkKyINdFErV0x8HQ3hKyZTYWEQFgZhYWggUute_LEEAU5-4ZzTPyDNXxHTDIIvjDdr0AR8PnZPRBZm_FkKxmx_0BjkO_BYzqfCAIORo3-I00Tr3edBX_R7D_fHaMNlwbvzfydoZTb9NKfAY2bqzNnpD4om75Y
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=Gynecologic+oncology+%28Print%29&rft.atitle=Adenocarcinoma+as+an+independent+risk+factor+for+disease+recurrence+in+patients+with+stage+IB+cervical+carcinoma&rft.au=EIFEL%2C+P.+J&rft.au=BURKE%2C+T.+W&rft.au=MORRIS%2C+M&rft.au=SMITH%2C+T.+L&rft.date=1995-10-01&rft.pub=Elsevier&rft.issn=0090-8258&rft.eissn=1095-6859&rft.volume=59&rft.issue=1&rft.spage=38&rft.epage=44&rft_id=info:doi/10.1006%2Fgyno.1995.1265&rft.externalDBID=n%2Fa&rft.externalDocID=3697185
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon